Jump to content

Rimeporide

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by JJMC89 bot III (talk | contribs) at 23:17, 12 August 2019 (Moving Category:Benzene sulfones to Category:Benzosulfones per Wikipedia:Categories for discussion/Speedy). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Rimeporide
Clinical data
ATC code
  • none
Legal status
Legal status
  • Experimental
Identifiers
  • N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H15N3O5S2
Molar mass333.38 g·mol−1
3D model (JSmol)
  • Cc1cc(c(cc1C(=O)NC(=N)N)S(=O)(=O)C)S(=O)(=O)C
  • InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15)
  • Key:GROMEQPXDKRRIE-UHFFFAOYSA-N

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation.[1] it has been granted orphan drug status by the European Medicines Agency.[2]

Mechanism of action

The substance blocks an ion pump called sodium–hydrogen antiporter 1 (NHE-1). While the exact mechanism is unknown, it is speculated that inhibition of this pump reduces sodium and calcium overload in cells of Duchenne patients.[1]

History

Rimeporide was designed as a treatment for chronic heart failure. It was unsuccessful in Phase I clinical trials, but was tolerated well by volunteers. Subsequently, the drug was sold to EspeRare, a Swiss nonprofit organisation[3] that aims at developing drugs for rare diseases. As of May 2015, the substance is in preclinical development for Duchenne.[1]

See also

Other drugs for Duchenne muscular dystrophy

References

  1. ^ a b c Spreitzer, Helmut (26 May 2015). "Neue Wirkstoffe – Rimeporid". Österreichische Apothekerzeitung (in German). 69 (11): 12.
  2. ^ "EspeRare's Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy". EspeRare. 4 May 2015.
  3. ^ "Our mission and vision". EspeRare. Retrieved 23 July 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Rimeporide&oldid=910565133"